The purpose of this study is to compare microwave ablation using the Acculis Microwave Tissue Ablation (MTA) System with conventional radiofrequency ablation (RFA) using Covidien cool-tip radiofrequency needle in patients with localized unresectabe hepatocelluar carcinoma (HCC). The investigators hypothesize that microwave ablation can achieve a better complete ablation rate as compared to radiofrerquency ablation. A randomized comparative study is performed by randomly assigned participants to microwave ablation arm or radiofrequency ablation arm. The efficacy of treatment outcome is assessed by the complete tumor ablation rate at 1 month, recurrence rate and survival time of participants. Safety of the procedures is also compared between the 2 treatment arms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
93
Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Prince of Wales Hospital
Hong Kong, China
Complete ablation rate
Measure by post-ablation Computed Tomography (CT) with reference to alpha-fetoprotein (AFP)
Time frame: 1 month
Treatment related mortality
Mortality within 30 days after operation
Time frame: 30-day
Recurrent disease
It is defined as the imaging detected new lesions
Time frame: 3 year
Survival
Overall and disease-free survival
Time frame: 3 year
Long-term liver function
Monitoring of liver function test result and the occurrance of decompensated cirrhosis
Time frame: 3 year
Treatment related morbidity
Complications related to the treatment received
Time frame: 30-day
Hospital stay
Total length of hospital stay (days)
Time frame: 30-day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.